PL4204421T3 - Związki i sposoby leczenia zakażeń wirusowych - Google Patents

Związki i sposoby leczenia zakażeń wirusowych

Info

Publication number
PL4204421T3
PL4204421T3 PL21770403.0T PL21770403T PL4204421T3 PL 4204421 T3 PL4204421 T3 PL 4204421T3 PL 21770403 T PL21770403 T PL 21770403T PL 4204421 T3 PL4204421 T3 PL 4204421T3
Authority
PL
Poland
Prior art keywords
compounds
treatment
methods
viral infections
infections
Prior art date
Application number
PL21770403.0T
Other languages
English (en)
Polish (pl)
Inventor
Elaine Bunyan
Byoung-Kwon Chun
Kassibla Elodie Dempah
Hon C. Hui
Rao V. KALLA
Richard L. Mackman
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4204421T3 publication Critical patent/PL4204421T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL21770403.0T 2020-08-27 2021-08-26 Związki i sposoby leczenia zakażeń wirusowych PL4204421T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063071134P 2020-08-27 2020-08-27
US202163162283P 2021-03-17 2021-03-17
US202163215310P 2021-06-25 2021-06-25
PCT/US2021/047800 WO2022047065A2 (en) 2020-08-27 2021-08-26 Compounds and methods for treatment of viral infections

Publications (1)

Publication Number Publication Date
PL4204421T3 true PL4204421T3 (pl) 2024-09-16

Family

ID=77775035

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21770403.0T PL4204421T3 (pl) 2020-08-27 2021-08-26 Związki i sposoby leczenia zakażeń wirusowych

Country Status (26)

Country Link
US (3) US11926645B2 (cg-RX-API-DMAC10.html)
EP (2) EP4424372A3 (cg-RX-API-DMAC10.html)
JP (2) JP7560659B2 (cg-RX-API-DMAC10.html)
KR (2) KR102833881B1 (cg-RX-API-DMAC10.html)
CN (2) CN121974913A (cg-RX-API-DMAC10.html)
AU (2) AU2021331214B2 (cg-RX-API-DMAC10.html)
CA (1) CA3190702A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023000555A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023002071A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230104A (cg-RX-API-DMAC10.html)
DK (1) DK4204421T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2023000041A (cg-RX-API-DMAC10.html)
ES (1) ES2985995T3 (cg-RX-API-DMAC10.html)
FI (1) FI4204421T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240733T1 (cg-RX-API-DMAC10.html)
HU (1) HUE067491T2 (cg-RX-API-DMAC10.html)
IL (1) IL300453A (cg-RX-API-DMAC10.html)
LT (1) LT4204421T (cg-RX-API-DMAC10.html)
MX (1) MX2023002195A (cg-RX-API-DMAC10.html)
PE (1) PE20231983A1 (cg-RX-API-DMAC10.html)
PL (1) PL4204421T3 (cg-RX-API-DMAC10.html)
PT (1) PT4204421T (cg-RX-API-DMAC10.html)
SI (1) SI4204421T1 (cg-RX-API-DMAC10.html)
TW (2) TW202233204A (cg-RX-API-DMAC10.html)
WO (1) WO2022047065A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA202301437B (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
DK3349758T3 (da) 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
CN113185519A (zh) * 2021-04-23 2021-07-30 苏州富德兆丰生化科技有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
CN118139868A (zh) * 2021-06-14 2024-06-04 维纳拓尔斯制药公司 口服生物可利用的核苷类似物
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
KR20240093977A (ko) * 2021-11-04 2024-06-24 선전 안티브이 파마 컴퍼니 리미티드 이소부티레이트 뉴클레오시드 화합물의 결정형 및 그 제조방법
EP4438606A4 (en) * 2021-12-23 2025-04-09 Shenzhen Antiv Pharma Co., Ltd. NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT
CN114516875B (zh) * 2022-01-26 2023-07-21 苏州旺山旺水生物医药有限公司 一种核苷类似物vv116的制备方法
JP2025508943A (ja) * 2022-03-02 2025-04-10 ギリアード サイエンシーズ, インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN114573590B (zh) * 2022-03-18 2023-11-14 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
CN116891474A (zh) * 2022-03-31 2023-10-17 苏州旺山旺水生物医药有限公司 一种单异丁酰基核苷类似物的制备方法
WO2023196458A1 (en) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
KR20240167065A (ko) * 2022-04-06 2024-11-26 선전 안티브이 파마 컴퍼니 리미티드 조성물 및 이의 제조 방법과 용도
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用
CN114805402A (zh) * 2022-05-13 2022-07-29 深圳安泰维生物医药有限公司 一种口服抗冠状病毒感染药物的大规模制备方法
WO2023222055A1 (zh) * 2022-05-17 2023-11-23 南京明德新药研发有限公司 氘代核苷化合物及其应用
US20250339377A1 (en) * 2022-05-27 2025-11-06 Shenzhen Antiv Pharma Co., Ltd. Pharmaceutical composition of nucleoside-derived compound, preparation method therefor, and use thereof
WO2023239665A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
JP2025523557A (ja) * 2022-06-28 2025-07-23 蘇州旺山旺水生物医薬股▲ふん▼有限公司 ネココロナ又はカリシウイルス感染を治療する方法
EP4547334A1 (en) * 2022-06-29 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
CN116874491B (zh) * 2022-07-12 2026-05-26 深圳安泰维生物医药有限公司 一种n-保护的吡咯并三嗪碳苷类化合物及其制备方法
CN115572298B (zh) * 2022-07-22 2024-11-08 苏州旺山旺水生物医药股份有限公司 一种核苷类似物及其盐的晶型、制备方法和应用
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
TWI866455B (zh) 2022-09-09 2024-12-11 美商基利科學股份有限公司 用於治療病毒感染之方法
CN115521316B (zh) * 2022-09-23 2024-07-26 深圳安泰维生物医药有限公司 一种核苷类化合物或其中间体的制备方法和核苷类化合物的中间体
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
WO2024091624A1 (en) 2022-10-27 2024-05-02 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN117815242B (zh) * 2023-01-05 2025-07-25 深圳安泰维生物医药有限公司 化合物atv014在抗新冠病毒感染中的应用
TW202545959A (zh) 2023-04-28 2025-12-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
EP4774275A1 (en) 2023-09-06 2026-07-15 Gilead Sciences, LLC Solid forms of a nucleoside analogue and uses thereof
CN121843949A (zh) 2023-09-15 2026-04-10 吉利德科学公司 用于治疗病毒感染的化合物和方法
KR20260079626A (ko) 2023-09-28 2026-06-02 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN122396692A (zh) 2023-12-22 2026-07-14 吉利德科学公司 核苷类似物的固体形式及其用途
WO2025147598A1 (en) * 2024-01-05 2025-07-10 Antiva Biosciences, Inc. Device system and use for hpv infection and cervical intraepithelial neoplasia
US20250276979A1 (en) 2024-02-07 2025-09-04 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
AU2025219283A1 (en) 2024-02-07 2026-08-06 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
JP2025161676A (ja) * 2024-04-11 2025-10-24 直江 博 病原性ウイルス及び血液性癌の治療器
CN118304315B (zh) * 2024-04-12 2025-03-25 深圳安泰维生物医药有限公司 一种核苷类化合物在制备抗呼吸道合胞病毒感染相关产品上的用途
WO2026060034A1 (en) 2024-09-11 2026-03-19 Gilead Sciences, Inc. Obeldesivir for the treatment of a coronavirus infection
WO2026060018A1 (en) 2024-09-11 2026-03-19 Gilead Sciences, Inc. Obeldesivir for the treatment of viral infections

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4894376A (en) 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
KR20010041533A (ko) 1998-03-03 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 (2e)-5-아미노-5-메틸헥스-2-엔오산n-메틸-n-((1r)-1-(n-메틸-n-((1r)-1-(메틸카르바모일)-2-페닐에틸)카르바모일)-2-(2-나프틸)에틸)아미드의신규한 염 형태
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
CN1127186C (zh) 1998-04-29 2003-11-05 中国科学院福建物质结构研究所 一种自锁模激光器
CN1147466C (zh) 1998-05-28 2004-04-28 华中理工大学 一种酰胺类化合物及其制备方法和用途
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
IL145496A0 (en) 1999-03-24 2002-06-30 Exiqon As Improved synthesis of [2.2.1] bicyclo nucleosides
WO2000075157A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE60105424T2 (de) 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
EP1337086B1 (en) 2002-02-13 2006-07-19 Matsushita Electric Industrial Co., Ltd. Method for transmitting data packets using RTP and RTCP protocols
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
BR0309581A (pt) 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
EP1646371A4 (en) 2003-06-26 2010-09-22 Biotron Ltd ANTIVIRAL COMPOSITIONS AND METHODS
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
US20050129764A1 (en) 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
JP2005187428A (ja) 2003-12-26 2005-07-14 Univ Of Tokyo 抗mgl抗体によるフィロウイルス治療薬
JP2005185235A (ja) 2003-12-26 2005-07-14 Univ Of Tokyo ウイルス感染に対する感受性診断のための方法およびキット。
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2005116165A1 (ja) 2004-05-31 2005-12-08 Dainippon Ink And Chemicals, Inc. 重合性液晶組成物及び光学異方体
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
CN2778310Y (zh) 2005-01-13 2006-05-10 中国人民解放军军事医学科学院野战输血研究所 心内膜注射导管
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
CA2602533A1 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8669280B2 (en) 2005-06-24 2014-03-11 Biotron Limited Antiviral compounds and methods
ES2436404T3 (es) 2005-10-03 2013-12-30 University Health Network Inhibidores ODCasa para el tratamiento de malaria
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
NO20055456L (no) 2005-11-17 2007-05-18 Fluens Synthesis As Kontinuerlig stromningsreaktor
SI1954264T1 (sl) 2005-12-01 2010-01-29 Basilea Pharmaceutica Ag Postopek priprave intermediatov epoksibutanola
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619563A2 (pt) 2005-12-09 2011-10-04 Pharmasset Inc nucleosìdeos antivirais
JP5112328B2 (ja) 2005-12-09 2013-01-09 バジリア ファルマスーチカ アーゲー 重度の皮膚科障害の局所的処置のための4−オキソ(イソ)トレチノイン
EP1987050A2 (en) 2006-02-14 2008-11-05 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
JP2010513484A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2155758T3 (da) * 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
ES2614269T3 (es) 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
PL2280973T3 (pl) * 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
BRPI1013643A2 (pt) * 2009-02-10 2016-04-19 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
MX2011009928A (es) 2009-03-24 2012-03-16 Biocryst Pharm Inc Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
KR20120051022A (ko) 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480552T3 (en) * 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011080568A2 (en) 2009-12-28 2011-07-07 Development Center For Biotechnology Novel pyrimidine compounds as mtor and p13k inhibitors
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之2’-氟取代之碳-核苷類似物
SG188223A1 (en) * 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
LT2898885T (lt) 2010-10-15 2018-02-26 Biocryst Pharmaceuticals, Inc. Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
EP2697241B1 (en) 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
ES2639122T3 (es) 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
EP2909209B1 (en) * 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
MX2015005949A (es) 2012-11-16 2015-09-08 Biocryst Pharm Inc Nucleosidos que contienen aza-azucar antiviral.
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9283242B2 (en) 2013-01-22 2016-03-15 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
PE20160686A1 (es) 2014-01-30 2016-07-23 Hoffmann La Roche Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015166434A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3250685A1 (en) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
JP6435054B2 (ja) 2015-02-11 2018-12-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染の治療及び予防のための新規2−オキソ−6,7−ジヒドロベンゾ[a]キノリジン−3−カルボン酸誘導体
DK3349758T3 (da) 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2018085307A1 (en) 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
EP3330276A1 (en) 2016-11-30 2018-06-06 Universität Bern Novel bicyclic nucleosides and oligomers prepared therefrom
CN108299532B (zh) 2016-12-29 2020-12-22 广东东阳光药业有限公司 一种抗病毒核苷类似物前药及其组合物、用途
TWI714820B (zh) * 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
BR112019016316A2 (pt) 2017-02-08 2020-03-31 Biotron Limited Métodos para o tratamento da influenza
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US11241491B2 (en) 2017-05-23 2022-02-08 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
US20190023745A1 (en) 2017-07-19 2019-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for zika virus vaccines
WO2019053696A1 (en) 2017-09-18 2019-03-21 Alios Biopharma, Inc. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
CN109748944B (zh) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN108084192B (zh) 2017-12-28 2020-06-05 大连微凯化学有限公司 一种微通道反应器进行氰基水解反应的方法
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
CN110330540A (zh) 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 核苷盐及其制备方法
WO2021040356A1 (en) 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
CN110724174B (zh) 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
US12600752B2 (en) 2019-11-20 2026-04-14 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
CN110776512A (zh) 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
WO2021154530A1 (en) 2020-01-27 2021-08-05 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
CN113248508B (zh) 2020-02-13 2024-12-06 安徽诺全药业有限公司 N-保护的杂环类化合物、其制备方法及其用于制备c-核苷衍生物的方法
CN111205327B (zh) 2020-02-17 2022-05-31 南京法恩化学有限公司 一种瑞德西韦的制备方法
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN111171078B (zh) * 2020-02-27 2022-04-22 江苏阿尔法药业股份有限公司 一种瑞德西韦的合成方法
CN111205294B (zh) 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
CN111233929B (zh) 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
WO2021175296A1 (zh) 2020-03-04 2021-09-10 中国科学院上海药物研究所 瑞德西韦的中间体及其制备方法
CN113387954B (zh) 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
CN111233869B (zh) 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
WO2021188915A1 (en) 2020-03-19 2021-09-23 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of coronavirus infection
WO2021195661A1 (en) 2020-03-23 2021-09-30 Gregg John M H Anti-viral compounds and methods for administration thereof
CN111548384B (zh) 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药
US12516080B2 (en) 2020-04-02 2026-01-06 The Regents Of The University Of Michigan Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111440176B (zh) 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
WO2021222807A1 (en) 2020-04-30 2021-11-04 Ajk Pharmaceutical Llc Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals
WO2021236570A1 (en) 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
CN111961057A (zh) 2020-05-26 2020-11-20 李小冬 一种α构型核苷及其在治疗猫冠状病毒感染的应用
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
WO2021248229A1 (en) * 2020-06-11 2021-12-16 Apotex Inc Novel crystalline form of remdesivir
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
LT4192839T (lt) 2020-08-06 2025-11-25 Remdesiviro tarpiniai junginiai
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
EP4203937A1 (en) 2020-08-28 2023-07-05 Sayvaa Pharmaceuticals Inc. Formulations of anti-viral compounds
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022081870A1 (en) 2020-10-14 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized norovirus virus-like particles as vaccine immunogens
WO2022093895A1 (en) 2020-10-27 2022-05-05 The University Of North Carolina At Chapel Hill Chimeric coronavirus s protein compositions and methods of use
WO2022098371A1 (en) 2020-11-09 2022-05-12 Yan Matthew Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment
CN114621229B (zh) 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN113754665B (zh) 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
CN116370479B (zh) 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
WO2022165386A1 (en) 2021-01-29 2022-08-04 Virbis Llc Lnp and lmp delivery of antiviral nucleotide 5'-phosphates
WO2022174194A1 (en) 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2022197950A1 (en) 2021-03-17 2022-09-22 The University Of North Carolina At Chapel Hill Methods and compositions for mature dengue viruses as vaccines and diagnostics
EP4319763A4 (en) 2021-04-09 2025-06-11 Emory University MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES
US20240166680A1 (en) 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
TWI845919B (zh) 2021-04-16 2024-06-21 美商基利科學股份有限公司 使用醯胺製備碳核苷之方法
CN113185519A (zh) * 2021-04-23 2021-07-30 苏州富德兆丰生化科技有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
US20240262857A1 (en) 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents
CN113698405B (zh) 2021-06-03 2022-09-27 南方科技大学坪山生物医药研究院 一种核苷类化合物的晶型及其制备方法
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
WO2023009977A1 (en) 2021-07-26 2023-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus chimeric therapeutics
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
WO2023102472A1 (en) 2021-12-01 2023-06-08 The Scripps Research Institute Antiviral prodrugs and formulations thereof
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN114409655A (zh) 2022-01-26 2022-04-29 郑州大学 3′,4′-不饱和核糖c-核苷类似物及其制备方法
JP2025508943A (ja) 2022-03-02 2025-04-10 ギリアード サイエンシーズ, インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN114437159B (zh) 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用
WO2023239665A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
EP4547334A1 (en) 2022-06-29 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
TWI866455B (zh) 2022-09-09 2024-12-11 美商基利科學股份有限公司 用於治療病毒感染之方法
CN115521316B (zh) 2022-09-23 2024-07-26 深圳安泰维生物医药有限公司 一种核苷类化合物或其中间体的制备方法和核苷类化合物的中间体
JP2025540572A (ja) 2022-11-18 2025-12-16 ギリアード サイエンシーズ, インコーポレイテッド ポックスウイルス感染を治療する方法
TW202545959A (zh) 2023-04-28 2025-12-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Also Published As

Publication number Publication date
FI4204421T3 (fi) 2024-06-25
JP2023540225A (ja) 2023-09-22
TW202228722A (zh) 2022-08-01
CL2023000555A1 (es) 2023-09-01
EP4204421A2 (en) 2023-07-05
EP4204421B1 (en) 2024-05-15
KR20250111239A (ko) 2025-07-22
IL300453A (en) 2023-04-01
PE20231983A1 (es) 2023-12-12
CN121974913A (zh) 2026-05-05
JP2024178294A (ja) 2024-12-24
US11926645B2 (en) 2024-03-12
HUE067491T2 (hu) 2024-10-28
CO2023002071A2 (es) 2023-05-29
CL2024000532A1 (es) 2024-09-23
CR20230104A (es) 2023-04-28
US20240317790A1 (en) 2024-09-26
HRP20240733T1 (hr) 2024-08-30
WO2022047065A3 (en) 2022-04-07
KR20230057411A (ko) 2023-04-28
KR102833881B1 (ko) 2025-07-15
DOP2023000041A (es) 2023-07-09
US20230151043A1 (en) 2023-05-18
PT4204421T (pt) 2024-06-25
JP7560659B2 (ja) 2024-10-02
TWI857241B (zh) 2024-10-01
AU2024202047A1 (en) 2024-04-18
TW202233204A (zh) 2022-09-01
DK4204421T3 (da) 2024-05-27
AU2021331214A9 (en) 2024-02-08
CA3190702A1 (en) 2022-03-03
AU2021331214A1 (en) 2023-05-04
CN116568688B (zh) 2025-11-21
ZA202301437B (en) 2025-03-26
AU2021331214B2 (en) 2024-01-04
US20220081462A1 (en) 2022-03-17
US12297226B2 (en) 2025-05-13
US11814406B2 (en) 2023-11-14
EP4424372A3 (en) 2024-12-18
ES2985995T3 (es) 2024-11-08
MX2023002195A (es) 2023-03-03
CN116568688A (zh) 2023-08-08
WO2022047065A2 (en) 2022-03-03
SI4204421T1 (sl) 2024-07-31
LT4204421T (lt) 2024-06-25
EP4424372A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
SI4204421T1 (sl) Spojine in postopki za zdravljenje virusnih okužb
IL315102A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
PL4157272T3 (pl) Remdesiwir do leczenia zakażeń wirusowych
IL290792B1 (en) Preparations and methods for treating viral infections
EP4243809A4 (en) COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS
GB2595513B (en) Treatment of infections
IL308478A (en) Methods and compositions for treating viral infection
GB202013874D0 (en) Treatment and prevention of viral infections
ZA202212662B (en) Use of compounds for treating viral infections
IL312285A (en) L-BHDU drugs and treatment methods for viral infections
EP4203965A4 (en) COMPOUNDS AND METHODS FOR PREVENTING AND TREATING VIRUS INFECTIONS
IL281447A (en) Methods and compositions for treating viral infections
GB202020502D0 (en) Antibody composistion for treatment of corona virus infection
IL288415A (en) Combinations and methods for the treatment of hemochromatosis
GB202312669D0 (en) Treatment of viral infections
GB202006160D0 (en) Treatment of viral infections
GB202004998D0 (en) Treatment of viral infections
GB202003232D0 (en) Treatment of viral infections
HUE067327T2 (hu) Vírusos légúti fertõzések kezelése
CA3304337A1 (en) Compounds and methods for treatment of viral infections
CA3303832A1 (en) Compounds and methods for treatment of viral infections
HK40123192A (en) Compounds and methods for treatment of viral infections
HK40106797A (en) Compounds and methods for treatment of viral infections
HK40087038A (en) Methods of treating viral infections
HK40124989A (en) Methods for treatment of viral infections including sars-cov-2